Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gendicine (rAd-p53) with Surgery in Advanced NSCLC
NCT01574729Phase 2Unknown
- Sponsor
- Shenzhen SiBiono GeneTech
- Start
- Aug 2012
- Primary completion
- Aug 2015
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of rAdp53 in non-small cell lung cancer (NSCLC), sponsored by Shenzhen SiBiono GeneTech. Status: unknown.
02
Drugs
rAdp53
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01574729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01574729.